TransMedia Group Retained To Publicize Launch Of Venodol, A New Over-The-Counter Roll-On Chronic Pain Relief Product

News provided by

Jul 17, 2017, 08:53 ET

BOCA RATON, Fla., Jul. 17, 2017 /PRNewswire/ -- TransMedia Group (www.TransMediaGroup.com) to roll on layers of publicity to introduce Venodol, a new over-the-counter analgesic product for the treatment of chronic pain with cobra venom as its active ingredient.

TransMedia said it plans to showcase Venodol's anti-inflammatory chronic pain relieving potential, while presenting the roll-on product as a non-addictive alternative to opioid and steroidal analgesics.

"We firmly believe Venodol is a gentler and safer approach to chronic pain relief," said Dr. Paul Reid, consulting advisor to Caretta Therapeutics, LLC, Venodol's manufacturer.

TransMedia Group says it will issue news releases, viral hashtags and conduct a variety of PR activities that will create national media exposure, some of it featuring credible spokespersons for Venodol.

As part of the PR campaign, TransMedia Group intends to partner with health publications in gathering feedback from product reviewers and reporting on Venodol's effectiveness in relieving chronic pain on a regular basis.

"We want to dispel any stigma around the use of cobra venom in a product for the treatment of chronic pain, and highlight its therapeutic potential to provide long-term relief," said TransMedia PR Director Rebecca Shpektor.

The makers of Venodol said their selection of TransMedia Group for publicity was based on the firm's history in successfully launching pain relief consumer products into drug store, mass merchandise and warehouse chains.

Media contact: Alexandra Flugel 561-750-9800 x2300; [email protected].

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Caretta Therapeutics' efforts to develop and commercialize Venodol, and to achieve its stated benchmarks including, without limitation, statements relating to if and when Caretta Therapeutics will succeed in making available products it is developing; and the benefits of Venodol. Actual outcomes and actual results could differ materially from those in such forward-looking statements. The forward-looking statements contained herein are made only as of the date of this press release and TransMedia Group undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE TransMedia Group